Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brexpiprazole - Lundbeck/Otsuka

Drug Profile

Brexpiprazole - Lundbeck/Otsuka

Alternative Names: Lu-AF41156; OPC-34712; OPC-34712 FUM; OPDC-34712; Rexulti; REXULTIOD; Rxulti

Latest Information Update: 02 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical Development & Commercialization
  • Developer Lundbeck A/S; Otsuka Beijing Research Institute; Otsuka Pharmaceutical Development & Commercialization; University of Chicago
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Piperazines; Quinolines; Sleep disorder therapies; Small molecules; Thiophenes
  • Mechanism of Action Dopamine D2 receptor partial agonists; Serotonin 1A receptor partial agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Agitation; Major depressive disorder; Schizophrenia
  • Phase III Bipolar disorders; Pervasive child development disorders; Post-traumatic stress disorders; Sleep disorders
  • Discontinued Attention-deficit hyperactivity disorder; Borderline personality disorders

Most Recent Events

  • 24 Jan 2024 Registered for Agitation in Canada (PO)
  • 22 Dec 2023 Registered for Major depressive disorder (Adjunctive treatment) in Japan (PO) (Otsuka Pharmaceutical pipeline, February 2024)
  • 06 Nov 2023 Efficacy and adverse events data from the phase III Study 213 trial in Agitation (in patients with dementia of the Alzheimer's type) were released by Otsuka Pharmaceutical and Lundbeck Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top